David K. Hooper, MD, MS

Medical Director of Kidney Transplantation

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4531

Fax 513-636-7407

Email david.hooper@cchmc.org

Nephrology; kidney transplantation; quality improvement

Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.

Dr. Hooper's research training includes a master's degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s.

Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.

MD: University of Utah, Salt Lake City, Utah, 2003.

Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.

Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.

MS: University of Cincinnati, Cincinnati, Ohio, 2010.

Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.

Certification: Pediatrics, 2006.

View PubMed Publications

Hooper DK, Kirby C, Margolis P, Goebel J. Reliable Individualized Monitoring Improves Cholesterol Control in Kidney Transplant Recipients. Pediatrics. 2013 Apr;131(4):e1271-9.

Hooper DK, Williams JC, Carle AC, Amaral S, Chand DH, Ferris ME, Patel HP, Licht C, Barletta GM, Bastian V, Mitsnesfes M, Patel UD. The Quality of Cardiovascular Disease Care and Formal Transition for Adolescents with Kidney Disease. Pediatr Nephrol. 2013 Jun;28(6):939-49.

Hooper DK, Fukuda T, Logan B, Gardiner R, Roy-Chaudhury A, Kirby C, Vinks A, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr;93(8):806-812.

Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam s, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of Successful Recruitment in Prospective Pediatric Pharmacogenetic Studies. Clinical Therapeutics. 2011 Feb;15:88-95.

Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.

Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.

Hooper DK. The Impact of CYP3A5 Genotype on the Interaction Between Tacrolimus and Intravenous Nicardipine in Kidney Transplant Recipients. University of Cincinnati. 2010 Aug 17.

Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4.

Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53.

Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.